Convalescent Plasma (anti-SARS-CoV-2 plasma)

BIOLOGICAL2 trials

Sponsors

Max O'Donnell, Andrew Eisenberger

Conditions

COVID-19SARS-CoV 2SARS-CoV-2 Infection

Phase 2

Plasma Therapy of COVID-19 in Severely Ill Patients

CompletedNCT04359810

Max O'DonnellSARS-CoV-2 Infection

Start: 2020-04-21End: 2020-12-30Updated: 2024-09-19

Convalescent Plasma for Early Treatment of COVID-19

TerminatedNCT04390503

Andrew EisenbergerCOVID-19, SARS-CoV 2

Start: 2021-03-12End: 2022-01-06Updated: 2024-08-28

Related Papers

A randomized double-blind controlled trial of convalescent plasma in adults with severe COVID-19

Journal of Clinical Investigation2021-05-11170 citations

Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial.

2020-06-0832 citations